Introduction
Chromosomal translocations can result in the generation of oncogenic fusion proteins that initiate the transformation of specific cell lineages (Rabbitts, 1998) . The nucelophosmin-anaplastic lymphoma kinase (NPM-ALK) is a fusion protein resulting from a t(2;5)(p23;q35) chromosomal translocation that occurs in non-Hodgkin's anaplastic large-cell lymphomas (ALCL) (Benharroch et al., 1998; Weisenburger et al., 2001; Falini and Mason, 2002) . In a review of 1117 ALCL patients, 53% were found to be positive for ALK protein . The translocation involves the gene loci encoding nucleophosmin (NPM) on chromosome 5 and anaplastic lymphoma kinase (ALK) on chromosome 2 (Morris et al., 1994) . The NPM gene encodes a bidirectional shuttle protein, accounting for the cytoplasmic and nuclear localization of NPM-ALK, although nuclear localization is not essential for transformation (Bischof et al., 1997; Mason et al., 1998) . ALK is a transmembrane receptor tyrosine kinase normally restricted in expression to neuronal tissue (Iwahara et al., 1997; Morris et al., 1997) . The fusion of 40% of the N-terminal portion of the NPM molecule with the complete intracytoplasmic tail of ALK leads to the NPM-dependent dimerization and consequent constitutive activation of the ALK tyrosine kinase (Bischof et al., 1997) with subsequent induction of mitogenic signals, as yet only partially characterized Greenland et al., 2001) . Several other fusion partners for ALK besides NPM have been reported, although NPM is the partner in 70-80% of ALCL cases (Falini et al., 1999) .
Expression of the active NPM-ALK kinase in haematopoietic cells is thought to initiate the events, which lead to the transformation of specific lineages . The term ALK-positive lymphoma or 'ALKoma' has been proposed to describe the group of ALK-positive lymphomas associated with the t(2:5) translocation (Benharroch et al., 1998) : these are characterized by lymphomas of T-cell or null-cell origin (Jaffe et al., 2001) , the 'null-cell' description reflecting the present clinical difficulty in identifying transformed non-T-cell lineages. Interestingly, a rare subset of diffuse large B-cell lymphoma aberrantly expressing the fulllength ALK protein has been described; such cases often show features of plasma cell differentiation . More recently, two cases of plasmablastic B-cell lymphoma expressing the NPM-ALK fusion protein have been described, which may represent a new disease entity (Onciu et al., 2003) .
Investigation of the oncogenic events mediated by NPM-ALK expression has been hampered by the lack of transgenic murine models. Retroviral transduction of murine bone marrow with the NPM-ALK transgene followed by adoptive transfer resulted in variable development of lymphomas of B-cell origin in a sample of four mice (Kuefer et al., 1997) . A more recent report describes the generation of T-and plasma-cell lymphomas in mice transgenic for NPM-ALK under the regulation of the T-cell-specific CD4 promoter (Chiarle et al., 2003) . In one transgenic line, there was a prevalence of plasma cell tumours (>80%), whereas in a different line thymic lymphomas were more common (>90%), and in a third line there was an equal presentation of thymic and plasma cell tumours. In the present work, we have generated mice transgenic for the human NPM-ALK gene under the control of the haematopoietic cell-specific Vav promoter. The Vav promoter becomes active in all haematopoietic lineages very early in differentiation. Use of this promoter thereby allows 'transgenic screening' of an oncogene in all haematopoietic lineages simultaneously. We describe the early-and late-onset development of phenotypically distinct lymphomas in two Vav-NPM/ALK transgenic lines expressing the transgene at different levels. These new lines facilitate the molecular analysis of the events leading from NPM-ALK expression to oncogenesis. Primary tumour cells are characterized by a remarkably high basal level of Jun kinase activity.
Results

Lymphomas in NPM-ALK transgenic mice
A vector was constructed incorporating human NPM-ALK cDNA under the regulation of the Vav promoter. Microinjections resulted in the birth of 103 mice, of which 10 carried the NPM-ALK transgene as determined by Southern blotting and PCR (data not shown). We observed germline integration of the transgene in the offspring of nine out of 10 of the transgene-positive mice. All lines and their offspring are healthy at ages reaching a maximum of 24 months except two of the Vav-NPM/ALK transgenic lines which developed lymphomas (Lines 1 and 3) (Tables 1  and 2 ). The most aggressive lymphomas developed in Line 3, generating a survival curve in which 100% of mice develop cancer in a narrowly defined time period from 91 to 225 days (Figure 1 ). In contrast, Line 1 mice did not begin to develop tumours until 270 days affecting, until now, 10% of a cohort of 78 mice (Figure 1 ). Dissection of Line 3 mice typically revealed tumours involving the mesenteric lymph nodes with metastases to various other tissues, invariably involving the intestines (Table 1) . In Line 1, tumours of the thymus, spleen, liver and lymph nodes were detected, with metastatic tissue involvement in some cases (Table 2) .
Expression of the NPM-ALK transgene
Southern blotting analysis indicated a copy number for the NPM-ALK transgene of 1 and 3 for Lines 1 and 3, respectively ( Figure 2b ). We could not detect NPM-ALK RNA transcripts, nor protein by immunoblotting, in any normal haematopoietic tissue of the Vav-NPM/ ALK mice (data not shown). In contrast, NPM-ALK transcripts were readily detectable in tumour tissue from Line 3 mice ( Figure 2a ) and Line 1 mice by RT-PCR (data not shown). NPM-ALK protein was also detectable in Line 3 tumour cell lysates by immunoblotting using an antibody specific for ALK protein (Figure 2c ). However, no ALK protein was detected in uninvolved thymic or splenic tissue from the Line 3 mouse in which NPM-ALK was easily measurable in a lymph node tumour ( Figure 2c ). Similar results were obtained by comparing Line 1 tumours and uninvolved tissues (data not shown).
Lineage analysis of lymphoma cells
Histopathological analysis of haematoxylin-eosinstained sections from Line 3 mice revealed variable involvement of bowel, lymph nodes, liver, spleen and mediastinum by a population of neoplastic cells with diffuse pattern of growth. Although features varied somewhat between individual mice, the tumour cells consistently had eccentrically placed nuclei. Some cases showed a 'clock-face' pattern of nuclear chromatin, while in others tumour cells had larger and more prominent single to multiple nucleoli. In all cases, there was the formation of a paranuclear hof. Together, the morphologic features were consistent with variable degrees of plasma cell differentiation in a diffuse large B-cell lymphoma (see Figure 3a -f, and flow cytometric data given below). Thymic involvement was occasionally seen but as an apparent secondary feature to diffuse mediastinal spread (Figure 3a and h) . Invasion of the intestines by tumour tissue was invariably observed (Figure 3d -f) and appeared to be associated with preexistent lymphoid tissue. Splenic involvement was characterized by ALK staining of a plasmacytoid tumour in the red pulp, whereas no staining of the white pulp was observed (Figure 3g ). Interestingly, strong ALK staining was observed in megakaryocytes in the splenic red pulp (Figure 3i) , showing that in certain cases NPM-ALK protein was detectable in normal tissue.
In contrast to the plasmacytoid features typical of Line 3 mice, the morphology of tumours from Line 1 mice was less distinct. Tumours typically involved the liver, but not the gut (Table 2 ) and showed a diffuse FACS analysis using a panel of haematopoietic expression markers showed that the tumours from both Lines 1 and 3 were consistently CD45 þ , confirming the haematopoietic lineage of all tumours. Interestingly, however, the panoply of expression markers was somewhat different for tumours from the two NPM-ALK lines, suggesting that the cells transforming in the earlyonset Line 3 and the late-onset Line 1 mice might have different origins. Line 3 tumours were typically positive for CD44, IgM, CD138, B220 and Gr1 (Ly-6G), and negative for CD3, CD4 and CD8 (Table 1) . CD138 is a marker for pre-B cells, immature B cells and plasma cells and is used in the clinic to identify tumours of this phenotype (Sebestyen et al., 1999; Sanderson and Borset, 2002) , whereas Gr-1 is normally expressed on myeloid lineages (Hestdal et al., 1991) . Since this particular repertoire of antigens is not usually expressed on the same B cell, we considered that the tumours might comprise a mixed population of cells. To investigate this possibility, we carried out four-colour staining and FACS analysis. Figure 4a shows that the population of cells positive for CD138 and IgM were also largely positive for Gr-1 and CD44, indicating that all four markers are expressed on the same tumour cells. Furthermore, Line 3 tumour cells were negative for c-kit and for the AA4 antigen (Li et al., 1996) , excluding a pre-B-cell phenotype, and also negative for CD5 (Table 1) , excluding the B1 mature peripheral B-cell phenotype (Hardy and Hayakawa, 2001) .
Line 1 tumours (Table 2 ) displayed considerable heterogeneity in their expression markers but were typically negative for T-cell markers (we think the Thy-1 observed in some tumours may be residual or infiltrating T cells) and positive for CD45 and CD44, with variable expression of IgM, CD138, CD30 and Mac-1 ( Figure 4b and Table 2 ). CD30 expression characterizes a clinically and pathologically heterogeneous group of human lymphomas, of which CD30 þ Hodgkin's lymphomas, ALCL and diffuse large B-cell lymphomas comprise important subsets (Maes et al., 2001; Morris et al., 2001) . Mac-1 (CD11b/CD18) is a myeloid marker but, unlike Line 3 tumour cells, Gr-1 expression was not often observed on Line 1 tumours. Some Line 1 tumours also expressed very early developmental markers such as c-kit and the AA4.1 antigen, a molecule found on stem cells and early B lineage cells (Li et al., 1996) . Four-colour FACS analysis showed that liver tumour cells from Mouse E6647 (Table 2) expressed IgM, CD44, CD30, Mac-1 and CD138 on the same cell population (data not shown), so although Line 1 tumours are different from Line 3 with respect to their histology and display of surface markers, they are similar in their coexpression of one or more myeloid markers. It should be noted in this context that there is a normal peripheral peritoneal B-1b subset that has the phenotype B220 Hardy and Hayakawa, 2001 ), so Mac-1 is not uniquely characteristic of the myeloid lineage. Overall, the main lineage differences between Lines 3 and 1 tumours are that Line 3 tumour cells usually express CD138 and Gr-1 but neither CD30 nor Mac-1, whereas the situation is reversed for Line 1 tumour cells. Line 3 tumours are generally plasmacytomas, whereas Line 1 tumours display a less differentiated B-cell phenotype.
Analysis of the clonality of tumours
To investigate the clonality of tumours, we measured H-chain VDJ rearrangements in tumour cell DNA by screening 7 V family members (Ehlich et al., 1994; ten Boekel et al., 1995; Corcoran et al., 1998) . We used the known clonotypic B-cell line Bal-17 as a positive control which, as expected, showed a single rearrangement (Figure 5, upper panel) . Line 1 tumours were either monoclonal or, possibly, oligoclonal. A definite conclusion is difficult because a nonreproductive rearrangement at one allele may lead to a second rearrangement in the same cell, yielding two different VDJ products. In contrast, Line 3 tumours were clearly oligoclonal, displaying a highly restricted ensemble of VDJ rearrangements ( Figure 5 ).
NPM-ALK expressed in tumour tissues is an active kinase phosphorylated at tyrosine residues and associates with the adaptor molecule shc It has previously been shown using cell lines established from human ALKomas that the hyperactive NPM-ALK tyrosine kinase fusion protein autophosphorylates, thereby functioning as a docking protein to recruit signalling proteins such as Shc (Fujimoto et al., 1996; Bai et al., 1998 Bai et al., , 2000 . It was therefore of interest to determine whether the NPM-ALK expressed in primary murine tumour tissue acted in the same way. Figure 6a shows that a 32 P-labelled protein migrated in the position of NPM-ALK following in vitro kinase assays in NPM-ALK immunoprecipitates from either Line 3 (lanes 1 and 2) or Line 1 (lane 3) tumours. Immunoblotting confirmed that phosphorylation was in tyrosine residues and the identification of NPM-ALK protein was established using Alk antibody (Figure 6a ). Interestingly, whereas NPM-ALK from a Line 1 tumour clearly possessed kinase activity, the immunoprecipitated protein was barely detectable by immunoblotting relative to the Line 3 signal. Although copy number is not necessarily an accurate guide to protein expression, these results are consistent with the higher transgene expression in Line 3 compared to Line 1. Figure 6b shows a comparison between the complex of autophosphorylated proteins associated with NPM-ALK in a Line 3 tumour (lane 1) compared to that found in human NPM-ALK þ SUDHL-1 cells (lane 3); an ALK immunoprecipitate from a Jurkat T-cell lysate was used as a negative control (lane 2). Interestingly, the profile of tyrosine phosphorylated proteins that form a complex with NPM-ALK differ Shc is an adaptor protein commonly associated with coupling to the Ras/MAP kinase pathway. We therefore investigated the state of activity of the various MAP kinase pathways in the tumour cells, in particular ERK, JNK and p38. As Figure 7a illustrates, levels of pJNK were highly elevated in Line 3 tumour cell lysates (lanes 2-4) and to a lesser extent in Line 1 lysates (lane 1). To assess the extent of activation, samples were compared with pJNK levels achieved in primary purified B cells following sIgM stimulation (Figure 7a , lanes 5 and 6).
This comparison revealed that basal pJNK levels were elevated >30-fold in Line 3 tumours when compared with stimulated B cells, and about fivefold in Line 1. A similar comparison for the ERK pathway showed that basal pERK in Line 3 tumour lysates was about fivefold higher than in stimulated B cells, whereas no increase was noted in Line 1 lysates (Figure 7a , lower panel). To measure Jun kinase activities more directly, we precipitated pJNK using a GST-c-Jun fusion protein bound to Sepharose beads. The ability of the bound pJNK to phosphorylate and hence activate GST-c-Jun was determined by immunoblotting using an antibody to pJun. Figure 7b shows that high levels of JNK activity were observed in Line 3 tumour precipitates (lanes 2 and 3) and to a lesser extent in a Line 1 tumour (lane 1). As a positive control primary B cells were exposed to UV light for 30 min (lane 6). It is striking that the level of Jun kinase activity in Line 3 tumour cells approached the activity induced by this very robust method of activating the JNK pathway. In contrast to these results, measurement of p38 activity as assayed by phosphospecific p38 antibodies revealed no increase in tumour cell lysates when compared with primary B cells (data not shown). Overall, these results show that there is a selective activation of the MAP kinase pathways in NPM-ALK-positive tumours involving JNK and, to a lesser extent, ERK.
Discussion
We have used the Vav promoter to generate transgenic mice that develop lymphomas expressing the NPM-ALK transgene. An advantage of the Vav promoter is that it causes early gene expression in all haematopoietic lineages (Ogilvy et al., 1999a, b) . This enables 'lineage screening' in which the potentially transforming effects of an oncogene can be compared in all haematopoietic compartments simultaneously. Interestingly, in the mouse context Vav-driven NPM-ALK expression causes B-cell lymphomas rather than tumours of null or T-cell phenotype normally observed in human NPM-ALK þ ALCL. Presumably, NPM-ALK expression following t(2:5) translocation in the clinical setting is controlled by the nucleophosmin promoter, a promoter as yet only partially characterized (Chan et al., 1997) . NPM is expressed ubiquitously, but the NPM promoter may vary in efficacy between lineages, and is unlikely to be mimicked precisely by the Vav promoter, possibly explaining the differences between mouse and human.
On the other hand, we have used the Vav promoter to make 11 transgenic lines expressing different CD45
isoforms (Ogilvy et al., 2003) and the expression levels were comparable in each line between different haematopoietic lineages, including T and B cells, so it appears unlikely that the B rather than T lineage transformation that we observe is explained by the differential efficacy of the Vav promoter between B and T cells. A recent publication by Chiarle et al. (2003) also describes the generation of plasmacytomas as a result of NPM-ALK expression in transgenic mice. This observation is somewhat puzzling as the transgene was under the regulation of the T-cell-specific CD4 promoter, suggesting either that the CD4 promoter is leaky and is expressed in other lineages or that CD4 is expressed transiently in a B-cell population that has not yet been defined. Either way there appears to be a preferential transformation of plasma cells in the murine context as a result of NPM-ALK expression.
The early-onset tumours of Vav-NPM/ALK Line 3 in comparison with the late-onset of Line 1 correlate with transgene copy number and protein expression ( Figure  2b and c), pointing to a finely tuned relationship between fusion protein expression levels and oncogenesis. Remarkably, NPM-ALK expression was readily detectable in Lines 1 and 3 in tumour cells (Figure 2 and 6), but not in uninvolved haematopoietic tissue, with rare exceptions (Figure 4i) . Expression of transgenic oncogenes in tumour tissue alone has previously been noted in other mouse models of leukaemia, in particular mice transgenic for Bcr-Abl under the control of the immunoglobulin heavy-chain enhancer (Hariharan et al., 1989) and mice transgenic for myc under the regulation of the CD2 promoter (Stewart et al., 1993) . A likely scenario is that low, undetectable NPM-ALK protein expression is sufficient to cause oncogenesis, consistent with the low copy number determined in both lines (Figure 2b) . It is also possible that founders with higher NPM-ALK expression levels die in utero or very early following birth and hence are not analysed. This could explain the low frequency (10/104) of founder animals carrying the transgene.
Although there was considerable heterogeneity between tumour phenotypes within each individual line, investigation of a large series of tumours (Tables 1 and 2) allowed some general conclusions. Line 3 tumours display plasmacytoid features histologically and their CD19
þ profile is characteristic of plasma cells. On the other hand, most tumours express sIgM and Gr-1 and during normal B-cell development plasma cells are negative for sIgM and neither do they express Gr-1, a myeloid cell marker. Nevertheless, it is not unusual for B lymphomas and other transformed cells to express ambiguous markers. For example, the myeloid marker CD15 is expressed on the surface of Reed-Sternberg cells in Hodgkin's lymphoma (Zukerberg et al., 1991) , whereas the human NK marker CD56 is expressed on some myeloid leukaemias and myelomas (Lanier and Hemperly, 1995) . Furthermore, it is possible that a small Gr-1 þ transitional cell population exists during normal B-cell development that has remained undetected until now and which is transformed in Line 3 mice. Another possibility arises from the hypothesis that early lymphoid precursors pass through a 'bipolar' stage of differentiation in which intermediates are characterized by either myeloid/B-or myeloid/T-cell phenotypes (Katsura, 2002) . Transformation of a myeloid/B-cell precursor followed by aberrant maturation could explain the ambiguous phenotype of Line 3 tumour cells.
In contrast to the early-onset Line 3 tumours, the lateonset Line 1 tumours often display a B220 (Table 2) , characteristic of peritoneal B1 cells (Hardy and Hayakawa, 2001) , so it is possible that transformation occurs at this developmental stage. Interestingly, both Lines 1 and 3 tumours appear to be monoclonal or oligoclonal with respect to their VD to J rearrangements ( Figure 5 ). The highly restricted repertoire of VD to J rearrarangements, together with the characteristic liver or lymph node/ spleen/gut involvement of Lines 1 and 3 tumours, respectively, are consistent with a model in which B cells mounting an immune response at specific tissue sites undergo subsequent transforming events. The wellestablished link between H. pylori infection and gastric mucosa-associated lymphoid tissue (MALT) B-cell lymphomas (Peek and Blaser, 2002) is similarly characterized by a limited repertoire of heavy-chain rearrangements in the lymphoma cells (Kanda et al., 2001) . The expression of the active NPM-ALK kinase may itself change the threshold for B-cell antigen receptor signal transduction, thereby modulating immune responses to foreign or self-antigens.
In the human, although Alk þ CD30 þ lymphomas are commonly of a T-lineage or 'null' phenotype , full-length Alk þ B-cell lymphomas have also been described Gascoyne et al., 1999) . More recently two cases of NPM-ALK expressing plasmablastic B-cell lymphomas have been reported (Onciu et al., 2003) . The current consensus is to reserve the term 'Alkoma' for Alk þ CD30 þ T and null cell lymphomas carrying the t(2;5) translocation and to classify Alk þ B-cell lymphomas along with other diffuse large B-cell non-Hodgkin's lymphomas . The rare diffuse large B-cell lymphomas that express full-length ALK protein display signs of plasma cell differentiation , so Line 3 NPM-ALK þ tumours may be more representative of this subclass and of the newly described plasmablastic cases (Onciu et al., 2003) .
Transgenic models of oncogenic fusion proteins have the advantage over retrovirus-mediated oncogene transfer into bone marrow (Kuefer et al., 1997) that they facilitate molecular investigation of tumours generated in a well-controlled physiological context in which the transgene expression is maintained at a constant level by the promoter. We investigated the MAP kinase pathways in NPM-ALK þ tumours in light of their wellestablished roles in mediating signals involved in cellcycle regulation and apoptosis. Unexpectedly, the Jun kinase activity in Line 3 tumours was found to be elevated more than 30-fold when compared to sIgMstimulated primary B cells, and fivefold increases were also noted in the ERK activation pathway (Figure 7) . It is possible that JNK activation is important in NPM-ALK þ tumour cell survival. Whereas in some cellular contexts stress-induced JNK activation appears to mediate apoptosis, in tumour cells JNK can signal cell survival (Davis, 2000; Kennedy and Davis, 2003) . When antisense JNK oligos were used to silence JNK, an inhibition of tumour growth and induction of apoptosis was observed (Bost et al., 1999; Potapova et al., 2000; Yang et al., 2003) . The JNK pathway activates an array of transcription factors associated with cell growth and differentiation, in particular the AP-1 transcription factor composed of jun-jun homodimers or jun-fos heterodimers. There is a binding site for the AP1 transcription factor in the NFkB promoter and JNK may therefore induce a survival signal via this pathway (Lamb et al., 2003) . The actions of c-Jun have also been implicated in the pathogenesis of hepatic carcinomas in a mechanism that involves the inactivation of the tumour suppressor protein p53, so preventing cell death (Eferl et al., 2003) and this regulation may be at the transcriptional level as c-Jun is able to repress the p53 promoter (Schreiber et al., 1999) . JNK is also implicated in cellular transformation by Bcr-Abl and cell survival by induction of the Bcl-2 protein (Dickens et al., 1997; Hess et al., 2002) . Further work will be necessary to determine whether hyperactive JNK is regulating the survival of Line 3 NPM-ALK þ tumour cells by comparable mechanisms. In addition, the marked activation of the p44/42 ERK Ras/MAP kinase pathway in Line 3 tumours (Figure 7 ) may contribute to the transforming process. This pathway is associated with the activation of a number of transcription factors, including c-myc, fos and ELK1, which regulate cell growth and differentiation. Furthermore, c-Jun and Ras have been shown to cooperate in the induction of tumour cell proliferation (Johnson et al., 1996) . The simultaneous activation of both the JNK and ERK pathways in Line 3 mice may therefore be implicated in the NPM-ALK-induced process of transformation.
Materials and methods
Cell line
The NPM-ALK-positive human T-cell lymphoma line, SUDHL-1 was maintained in RPMI-1640 plus glutamine supplemented with 10% FBS, penicillin and streptomycin.
Generation of NPM-ALK transgenie mice
The human NPM-ALK cDNA was isolated from the pcDNA 3 NPM-ALK vector (from Professor S Morris, St Jude Childrens Research Hospital, Memphis, TN, USA). A NotI site was created using linkers at the ApaI site, and the B2.5 kb fragment encoding NPM-ALK was then ligated into the Vav promoter vector at the Eag1 site (Ogilvy et al., 1999a) . The newly created Vav/NPM-ALK vector was prepared for microinjection by removing prokaryotic sequences with a HindIII digest followed by gel purification. The 11 kb fragment was injected into the pronuclei of eggs from C57BL/6J Â CBA F1 mice and the microinjected eggs were transferred to the ovarian ducts of pseudopregnant recipients.
Genotyping of mice
Mice were genotyped from tail tissue biopsies by both PCR and Southern blot. A 1.7 kb BamHI fragment of pcDNA 3 NPM-ALK was used as a probe for Southern blotting. PCR was carried out using primers specific for human NPM-ALK spanning the NPM-ALK fusion junction: NPM sense 5 0 -TCCCTTGGGGGCTTTGAAATAACACC3 0 , ALK antisense 5 0 -CGAGGTGCGGAGCTTGCTCAGC3 0 . Copy number was determined by Southern blot using a SacI fragment of the Vav promoter. The probe hybridizes to a 3.6 kb fragment of the transgenic Vav and a 5 kb fragment of the endogenous Vav promoter following digestion of DNA with SacI.
RNA extraction and RT-PCR
mRNA was extracted from the tissues of transgenic mice using a micro-polyA mRNA extraction kit (Ambion, Austin, TX, USA). Isolated mRNA was then treated with deoxyribonuclease I (Sigma, Dorset, UK) before reverse transcription (Ambion Retroscript kit) and PCR as described above. The presence of any contaminating DNA was accounted for by PCR of nontranscribed mRNA samples. RT-PCR was also carried out for a housekeeping gene to check the integrity of the isolated mRNA (Ambion Retroscript kit).
Western blot analysis
Tissues were homogenized in 3% Brij-96 lysis buffer (20 mM NaPO 4 , pH 7.5, 50 mM NaF, 0.1 mM Na 3 VO 4 , 150 mM NaCl, 10 mM EDTA, 10 mM EGTA and protease inhibitors) and proteins were separated by 8% SDS-PAGE. The NPM-ALK presence was detected using a mouse monoclonal antibody to human ALK (ALK1) on polyvinylidene membranes . Phospho-antibodies (p-ERK, p-JNK, p-jun), and anti-JNK were purchased from Cell Signalling Technology (Beverly, MA, USA). Anti-ERK 2 and anti-c-jun were purchased from Santa Cruz (Santa Cruz, CA, USA).
Immunoprecipitation
Disaggregated tumour tissue was lysed in 1 ml of 3% Brij-96 lysis buffer followed by one round of preclearing with 50 ml of Protein-G beads for 1 h at 41C. The precleared lysate was then incubated for 2 h at 41C with 50 ml of Protein-G beads preloaded with ALK1 antibody. The immunoprecipitates were washed eight times with cold lysis buffer followed by separation using 8% SDS-PAGE. Proteins were immunoblotted with PY100 phosphotyrosine mAb (Cell Signalling Technologies, Beverley, MA, USA), ALK11 antibody or a SHC polyclonal antibody (Upstate Biotechnology, Lake Placid, NY, USA). Bands were visualized using ECL (Amersham Pharmacia, Bucks, UK) followed by exposure to film (Hyperfilm ECL, Amersham Pharmacia, Bucks, UK) or a phosphorimager (Fuji LAS 1000) followed by analysis with AIDA software.
NPM-ALK kinase assay
Following immunoprecipitation of NPM-ALK as described above, 20 ml of kinase buffer (100 mM NaCl, 20 mM HEPES pH 7.5, 5 mM MgCl 2 , 5 mM MnCl 2 , 10 mM ATP, 1 ml 32 P-gATP, 5 mCi/ml) was added to the Sepharose beads followed by incubation for 20 min at room temperature with shaking. The beads were pelleted at 12 000 g and the supernatant was discarded. The immunoprecipitates were then washed twice with 200 ml of chilled lysis buffer prior to SDS-PAGE and transferred to Immobilon membrane (Millipore) before analysis using a Fuji FLA3000 phoshorimager.
Histopathological studies
When mice were found dead or moribund, autopsies were performed examining all tissues. Diseased tissue was fixed in 10% buffered formalin. Fixed tissues were paraffin processed and sections were stained with haematoxylin-eosin according to standard protocols. Immunohistochemistry was performed using a rabbit polyclonal antibody for human ALK (ALK11) (from Professor S Morris, St Jude Childrens Research Hospital, Memphis, TN, USA) (Morris et al., 1995) and DAKO EnVision þ t/HRP, Rabbit, DAB system (Ely, Cambs, UK).
FACS analysis of tumour cells
Disaggregated tumour tissue was washed 2 Â in PBS before staining 1 Â 10 6 cells for 30 min at 41C with FITC-conjugated antibodies. A panel of antibodies was used including CD45, CD30, B220, CD19, IgM, IgD, CD3, Thy-1, CD4, CD8, CD25, CD43, CD44, Mac-1, Gr-1, CD138, CD79a, CD79b, CDS, AA4.1 and c-kit (BD Pharmingen, San Diego, CA, USA). Analysis of results was carried out using CELLQuest software (Becton Dickinson, San Diego, CA, USA).
Analysis of heavy-chain rearrangements in tumour tissue
DNA was prepared from tumour cells using standard techniques. Regions of VD-J DNA were amplified using 5 0 primers specific to seven different V family members. A 3 0 primer downstream of J4 common to all rearrangements was used: 5 0 -GGGTCTAGACTCTCAGCCGGCTCC-CTCAGGG-3 0 . The primers were employed in a PCR: one cycle of 961C 3 min, two cycles of 941C for 40 s, 651C for 45 s, 721C for 1 min 45 s, three cycles of 941C for 40 s, 631C for 45 s, 721C for 1 min 45 s; plus 20 cycles of 941C for 40 s, 601C for 45 s, 721C for 1 min 45 s (Corcoran et al., 1998) . PCR products were visualized on a 1% agarose gel.
Jun kinase assay
Brij96 lysates of mouse tumour cells or primary murine B cells were rotated at 41C overnight with Sepharose beads prebound to a GST-c-Jun fusion protein. The beads were then washed two times with lysis buffer (1 mM EDTA, 1 mM EGTA, 1% Triton-X, 20 mM Tris, pH 7.4, 150 mM NaCl, 25 mM Na pyrophosphate, 1 mM Na 3 VO 4 and 1 mM b-glycerophosphate) followed by two washes with kinase buffer (25 mM Tris, pH 7.5, 5 mM b-glycerophosphate, 2 mM DTT, 0.1 mM Na 3 VO 4 and 10 mM MgCl 2 ) followed by resuspension in kinase buffer containing 100 mM ATP for 30 min at 301C. The beads were then washed several times with ice-cold lysis buffer before solubilization in sample buffer. Proteins were separated on a 10% SDS-PAGE gel.
